ReviewJournal of applied microbiology2016
Biomedical applications of nisin.
Review in Journal of applied microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 252 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
252 citing papers in PubMed, 1 synthesis or guideline pooled it, 587 citations in OpenAlex.
- Peptide Designs for Use in Caries Management: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Effectiveness of experimental composites containing antimicrobial agents for orthodontic applications.Odontology · 2026Article
- Targeting Eustachian Tube Microenvironment: Probiotic Surfactant Utilization for Antimicrobial Peptide Secretion to Prevent Otitis Media.Probiotics and antimicrobial proteins · 2026Review
- Article
- Lactic Acid Bacteria-Derived Antimicrobial and Anti-Biofilm Strategies: Mechanisms, Functional Molecules, and Emerging Biomaterial Applications.International journal of molecular sciences · 2026Review
- Use of Micro/Nanorobots In Vivo for the Eradication of Bacterial Biofilm: A Review of Challenges and Strategies.Nanomaterials (Basel, Switzerland) · 2026Review
- In Vitro Assessment of Selected Postbiotic Substances Against Methicillin-Resistant and Methicillin-SusceptibleAnimals : an open access journal from MDPI · 2026Article
- Antibacterial Potential ofFoods (Basel, Switzerland) · 2026Article
- Enhancing the Antitumor Efficacy of Nisin Through Advanced Nanosystems: A Systematic Review of In Vitro Studies.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Green synthesis of nisin-loaded pectin based silver nanoparticles and their antimicrobial and biosafety assessment.Discover nano · 2026Article
- Review
- Nisin bacteriocin blocks T. denticola-triggered MMP2 activation and pathogen internalization via TLR2.Scientific reports · 2026Article
- Periodontitis and respiratory infections - exploring the oral-systemic link.Annals of medicine and surgery (2012) · 2026Article
- A comparative framework of natural nisin variants: linking genetic basis to future bioengineering applications.Microbial cell factories · 2026Review
- Role and Mechanisms of Gut Microbiota in Infectious Diseases: Recent Evidence from Animal Models.Biology · 2026Review
- Postbiotics at the interface of microbial biotechnology and therapeutics: industrial production, functional mechanisms, and clinical potentials.Archives of microbiology · 2026Review
- Antimicrobial Peptides Against Antimicrobial-Resistant Bacteria: Focus on Machine Learning.Infection and drug resistance · 2026Review
- Antimicrobial Efficacy of Calcium Hydroxide Nanoparticles Combined with Nisin Against Enterococcus Faecalis in Root Canal Infections ��� an Ex Vivo Study.European endodontic journal · 2025Article
- The antimicrobial metabolite nisin Z reduces intestinal tumorigenesis and modulates the cecal microbiome in ApcMicrobiology spectrum · 2025Article
- Article
192 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Nisin is a bacteriocin produced by a group of Gram-positive bacteria that belongs to Lactococcus and Streptococcus species. Nisin is classified as a Type A (I) lantibiotic that is synthesized from mRNA and the translated peptide contains several unusual amino acids due to post-translational modifications. Over the past few decades, nisin has been used widely as a food biopreservative. Since then, many natural and genetically modified variants of nisin have been identified and studied for their unique antimicrobial properties. Nisin is FDA approved and generally regarded as a safe peptide with recognized potential for clinical use. Over the past two decades the application of nisin has been extended to biomedical fields. Studies have reported that nisin can prevent the growth of drug-resistant bacterial strains, such as methicillin-resistant Staphylococcus aureus, Streptococcus pneumoniae, Enterococci and Clostridium difficile. Nisin has now been shown to have antimicrobial activity against both Gram-positive and Gram-negative disease-associated pathogens. Nisin has been reported to have anti-biofilm properties and can work synergistically in combination with conventional therapeutic drugs. In addition, like host-defence peptides, nisin may activate the adaptive immune response and have an immunomodulatory role. Increasing evidence indicates that nisin can influence the growth of tumours and exhibit selective cytotoxicity towards cancer cells. Collectively, the application of nisin has advanced beyond its role as a food biopreservative. Thus, this review will describe and compare studies on nisin and provide insight into its future biomedical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.